Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Expenses:
Research and development	$ 9,253	$ 10,797
General, and administrative	9,892	9,295
Operating expenses	19,145	20,092
Operating loss	(19,145)	(20,092)
Other income:
Other income, net	132	740
Total other income, net	132	740
Net loss before benefit from income taxes and noncontrolling interests	(19,013)	(19,352)
Benefit from income taxes	(10,872)	0
Net loss	(8,141)	(19,352)
Less - net income attributable to noncontrolling interests	9	9
Net loss attributable to Caladrius Biosciences, Inc. common shareholders	$ (8,150)	$ (19,361)
Basic and diluted loss per share:
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders (in dollars per share)	$ (0.53)	$ (1.88)
Weighted average common shares outstanding:
Basic and diluted weighted average common shares outstanding (shares)	15,440	10,325